论文部分内容阅读
目的:评价吗替麦考酚酯与泼尼松联用对儿童紫癜性肾炎患者的临床疗效。方法:选取2013年12月—2015年3月间收治的紫癜性肾炎患者90例,将其分为观察组(46例)和对照组(44例);观察组患者均给予泼尼松与吗替麦考酚酯(MMF)联用治疗,对照组患者均给予泼尼松与环磷酰胺(CTX)联用冲击治疗,比较两组患者的临床疗效和治疗前后的实验室指标及不良反应发生情况。结果:观察组患者的临床治疗总有效率为97.83%,明显高于对照组为79.55%(P<0.05);观察组患者不良反应的发生率为4.35%,明显低于对照组为20.45%(P<0.05);观察组患者治疗后24 h尿蛋白定量值、尿红细胞计数值明显低于对照组患者(P<0.05)。结论:吗替麦考酚酯与泼尼松联用对儿童紫癜性肾炎患者的临床疗效优于泼尼松与环磷酰胺(CTX)联用治疗,且疗效较显著,不良反应较少。
Objective: To evaluate the clinical efficacy of mycophenolate mofetil and prednisone in children with purpura nephritis. Methods: Ninety patients with purpura nephritis admitted from December 2013 to March 2015 were divided into observation group (46 cases) and control group (44 cases). Patients in observation group were given prednisone with In combination with mycophenolate mofetil (MMF), patients in the control group were given both prednisone and cyclophosphamide (CTX) in combination with shock therapy. The clinical efficacy and laboratory parameters and adverse reactions before and after treatment were compared between the two groups Happening. Results: The total effective rate of clinical treatment in observation group was 97.83%, which was significantly higher than that in control group (79.55%, P <0.05). The incidence of adverse reactions in observation group was 4.35%, which was significantly lower than that in control group (20.45% P <0.05). After 24 hours of treatment, urinary protein and urinary erythrocyte count of patients in observation group were significantly lower than those in control group (P <0.05). Conclusion: The mycophenolate mofetil and prednisone combined with prednisone in children with clinical treatment of purpura nephritis is superior to the combination of prednisone and cyclophosphamide (CTX) treatment, and the more effective, less adverse reactions.